Newer therapies for chronic obstructive pulmonary disease

Journal of Association of Physicians of India

Volumn 60, Issue SUPPL FEB2012, 2012, Pages 8-13

  Kodgule, Rahul ^a   Vaidya, Abhijit ^b   Salvi, Sundeep ^a  

^a Chest Research Foundation   (India)

^b CIPLA LTD   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG DEVELOPMENT; DRUG THERAPY; HUMAN; PATHOPHYSIOLOGY; REGENERATIVE MEDICINE; REVIEW; STEM CELL TRANSPLANTATION;

CHRONIC DISEASE; DRUG DISCOVERY; DRUG THERAPY; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REGENERATIVE MEDICINE; STEM CELL TRANSPLANTATION;

EID: 84871909915     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Sundeep S Salvi, Peter J Barnes. Chronic obstructive pulmonary disease in non-smokers. Lancet 2009;374:733-43.
2. William MacNee, and Rubin M. Tuder. New Paradigms in the Pathogenesis of Chronic Obstructive Pulmonary Disease I. Proc Am Thorac Soc 2009;6:527-531.
3. Leonardo M. Fabbri, Fabrizio Luppi, Bianca Beghé, and Klaus F. Rabe. Update in Chronic Obstructive Pulmonary Disease 2005. Am J Respir Crit Care Med 2006;173:1056-1065.
4. Barnes PJ. Mediators of Chronic Obstructive Pulmonary Disease. Pharmacol Rev 2004;56:515-548.
5. Irfan Rahman. Review: Antioxidant therapeutic advances in COPD. Ther Adv Respir Dis 2008;2:351-74.
6. William MacNee. Oxidants/Antioxidants and COPD. Chest 2000;117;303S-317S.
7. Z. Kluchová, D. Petrášová1, P. Joppa, Z. Dorková, R. Tkáčová. The Association between Oxidative Stress and Obstructive Lung Impairment in Patients with COPD. Physiol Res 2007;56:51-56.
8. Jacques Cornuz. A Vaccine against Nicotine for Smoking Cessation: A Randomized Controlled Trial. PLoS ONE 3(6): e2547. doi:10.1371/journal.pone.0002547
9. Carola Seifart and Claus Vogelmeier. Emerging drugs in chronic obstructive pulmonary diseases. Expert Opinion. Emerging Drugs 2009;14:181-194
10. Peter J. Barnes. Emerging Pharmacotherapies for COPD. Chest 2008;134;1278-1286
11. Peter J. Barnes. Future Treatments for Chronic Obstructive Pulmonary Disease and Its Comorbidities. The Proceedings of the American Thoracic Society 2008;5:857-864
12. Satomi Onoue, Shinger Misaka, Yohei Kawabata and Shizuo Yamada. New treatments for chronic obstructive pulmonary disease and viable formulation/device options for inhalation therapy. Expert Opin. Drug Deliv 2009;6:793-811.
13. Matera MG, Page CP, Cazzola M. Novel bronchodilators for the treatment of chronic obstructive pulmonary disease. Trends in Pharmacological Sciences 2011;1-12. Article in Press.
14. M. Cazzola and M.G. Matera. Emerging inhaled bronchodilators: an update. Eur Respir J 2009;34:757-769.
15. M Cazzola and MG Matera. Novel long-acting bronchodilators for COPD and Asthma. British Journal of Pharmacology 2008;155:291-299
16. Jean Bourbeau and Malcolm Johnson. New and Controversial Therapies for Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc 2009;6:553-554,
17. D.J. Powrie et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur Respir J 2007;30:472-478.
18. Becky J. Proskocil and Allison D. Fryer. β2-Agonist and Anticholinergic Drugs in the Treatment of Lung Disease. Proc Am Thorac Soc 2005;2:305-310
19. Douglas W Mapela, Judith S Hurleyb, Anand A Dalalc, Christopher M Blanchetted. The role of combination inhaled corticosteroid/long-acting β-agonist therapy in COPD management. Primary Care Respiratory Journal 2010;ahead of print.
20. Barnes PJ. Triple inhalers for obstructive airways disease: will they be useful? Expert Rev Respir Med 2011;5:297-300.
21. P J Barnes. Theophylline for COPD. Thorax 2006;61:742-744.
22. Peter J. Barnes. Theophylline. New Perspectives for an Old Drug. Am J Respir Crit Care Med 2003;167:813-818.
23. Barnes PJ. Role of HDAC2 in the pathophysiology of COPD. Annu Rev Physiol 2009;71:451-64.
24. Peter M. A. Calverley et al. Effect of 1-Year Treatment with Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2007;176:154-161
25. Klaus F Rabe, Eric D Bateman, Denis O'Donnell, Stephan Witte, Dirk Bredenbröker, Thomas D Bethke. Roflumilast-an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 2005;366:563-71
26. Victoria Boswell-Smith, Domenico Spina and Clive P. Page. Phosphodiesterase inhibitors. British Journal of Pharmacology 2006;147:S252-S257.
27. Giembycz MA, Field SK. Roflumilast: first phosphodiesterase-4 inhibitor approved for treatment of COPD. Drug Design, Development and Therapy 2010;4:147-58.
28. Irfan Rahman. Antioxidant therapies in COPD. International Journal of COPD 2006;1:15-29.
29. Brashier B, Ravindaran L, Kapoor S, Deshpande PK, Ghongane B, Madas S, Mandrekar S, Limaye S, Salvi S. Four weeks of treatment with n-acetyl cysteine (NAC) (1200mg/day) reduces lung oxidative stress and improves lung function in moderate-to-severe COPD subjects. European Respiratory Society Congress 2009;Abstract 2016.
30. Aruna Kode, Saravanan Rajendrasozhan, Samuel Caito, Se-Ran Yang, Ian L. Megson, and Irfan Rahman. Resveratrol induces glutathione synthesis by activation of Nrf2 and protects against cigarette smoke-mediated oxidative stress in human lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 2008;294:L478-L488.
31. Yasujiro Morimitsu et al. A Sulforaphane Analogue That Potently Activates the Nrf2-dependent Detoxification Pathway. The Journal of Biological Chemistry 2002;277:3456-3463.
32. Claudia C Dobler, Keith K Wong and Guy B Marks. Associations between statins and COPD: a systematic review BMC Pulmonary Medicine 2009;9:32
33. Eric M Mortensen Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respiratory Research 2009;10:45
34. B. John Mancini et al. Reduction of Morbidity and Mortality by Statins, Angiotensin-Converting Enzyme Inhibitors, and Angiotensin Receptor Blockers in Patients With Chronic Obstructive Pulmonary Disease. Journal of the American College of Cardiology 2006;47:12,
35. Francine Z. Marques, M. Andrea Markus, Brian J. Morris Resveratrol: Cellular actions of a potent natural chemical that confers a diversity of health benefits. The International Journal of Biochemistry & Cell Biology 2009;41:2125-2128.